American Capital, Ltd. (ACAS) opening the day at $17.33. The company has seen its stock increase in value by 24.44% so far this year. The stock was down close to -0.98% on active volume in last trading session and closed at $17.16 per share. After the recent fall, the stock is currently holding -3.27% below its 52 week high of $17.74 and 41.35% above its 12-month low of $12.14. The shares are up by over 2.02% in the last three months, and the RSI indicator value of 44.13 is neither bullish nor bearish, tempting investors to stay on the sidelines.
American Capital, Ltd. is a business development company specializing in management and employee buyouts, subordinated debt, leveraged finance, mezzanine, acquisition, recapitalization, middle market, early venture, mature, industry consolidation, and growth capital investments. The firm seeks to invest in senior debt mezzanine, unitranche, and equity financing for buyouts of private equity firms and direct in private and public companies. It also invests in special situations and in government. In special situations, the firm invests in troubled situations and in distressed situations. The firm also considers smaller investments as add-on acquisitions for existing portfolio companies. In this area, it invests in acquisitions of true turnarounds, 363 auctions, portfolio add-on acquisitions, operationally challenged companies; financings in exit, ABL loans, second lien refinance, and direct lending to distressed companies. The firm invests in manufacturing, services, and distribution companies with a special focus on energy sector. The firm also invests in infrastructure and structured products. The firm also invests in business services, consumer products and services, industrial, healthcare and food companies. The firm prefers to invest in Information Technology focusing on Custom information technology solutions, Technology and software enabling headcount reduction, and Technology and software enabling cost reductions in conducting transactions with or within government. The firm also invests in digital media and entertainment, internet and consumer related, communications, mobile and wireless, security and data center infrastructure, software and services, semiconductor, and other innovative technologies. The firm also invests in a variety of industry sectors, including life science services, medical device, medical tools and equipment, and healthcare services, among others. In energy production sector, the firm invests in lower risk oil and gas exploration, production and development; natural gas liquids; coal mining and coal-fired generation; uranium mining and nuclear-fired generation; wind-powered generation; and solar-powered generation. In energy transmission sector, the firm invests in oil and gas pipelines; LNG tankers and regasification facilities; and power transmission. In energy distribution sector, it targets propane distribution; gas distribution; electricity distribution. In energy services sector, the firm invests in oil and gas services and utility services. The firm also targets investments in companies that provide services or products to federal, state or local governments. It seeks to invest in human resources/benefit administration, outsourcing, transaction processing, engineering and construction, logistics, original equipment manufacturers homeland security and component, aftermarket parts and supplies, and technology. It also invests in real estate and insurance. It invests as lead or participative investor and also makes equity co-investments. The firm seeks to invest globally focusing on Middle East, North Africa, South Asia, Mid-Atlantic, New England, North East Unites States, Canada, Central America & Mexico, and Caribbean. The firm and its affiliates invest between $10 million to $750 million per company in North America and 10 ($13.34 million) to 400 million ($533.99 million) per company in Europe. The firms investment range is between $5 million and $25 million and higher depending on the opportunity. The firm targets new investments with at least $10 million in EBITDA and enterprise values of typical transaction from $20 million and $500 million. The firm invests senior debt, subordinated debt and equity allows us to provide one-stop financing up to $500 million. The firm also has the resources to deploy over $100 million into high growth later stage companies. In special situations group, the firm invests between $20 million and $750 million per transaction in a variety of investments, including: buyouts operational turnarounds, corporate orphans and carve-outs, complex management buyouts, financings dip financings, exit financings, and mezzanine financings for sponsored buyouts. In buyouts, the firm invests in companies having Enterprise Value of up to $1600 million. In federal, state and local government, the firm invests between $10 million and $500 million in a single transaction. The firm prefers to be a majority or minority investor and makes direct minority investments of subordinated debt, senior debt and equity in middle market private and public companies. The firm prefers to take minority ownership position of up to 49%. American Capital, Ltd., formerly known as American Capital Strategies, Ltd., was founded in 1986 and is based in Bethesda, Maryland with additional offices in United States, Europe, Africa, and Asia.
Pacific Biosciences of California, Inc. (PACB) continued its downward trend with the stock declining -43.62% or $-3.01 to close the day at $3.89 on light trading volume of 10.8M shares, compared to its three month average trading volume of 984.85K. The Menlo Park California 94025 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -61.56%, compared to the industry which has dropped -6.49% over the same period. With RSI of 13.74, the stock should still continue to rise and get closer to its one year target estimate of $11.67, making it a hold for now.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The companys single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions. The company also provides consumable products, including sealed and packaged SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits to run the PacBio RS II or Sequel System. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distributors in Asia. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
CVS Health Corporation (CVS) dropped $-0.67 to close the day at a new closing price of $78.29, a -0.85% decrease in value from its previous closing price that moved the stock 12.97% above its 52 week low of $69.3. A total of 10.62M shares exchanged hands during the day compared with its three month average trading volume of 8.4M. The stock, which fluctuated between $76.11 and $79.24 during the day, currently situated -25.92% below its 52 week high. The stock is up by 4.33% in the past one month and down by -12.7% over the past three months. With a one year target estimate of $86.79 and RSI of 48.21, the stock still has upside potential, making it a hold for now.
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, managed Medicaid plans and plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS Pharmacy, CVS Specialty, Accordant, SilverScript, NovoLogix, Coram, Navarro Health Services, and Advanced Care Scripts names. As of December 31, 2015, it operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies and 5 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail/LTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as provides photo finishing services. It operates 9,655 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 32 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.